The increased use of telehealth could substantially improve access to needed treatments and compliance with them. Is that good enough a driver for pharmaceutical companies? Not only is there a surge in utilization of telehealth across the globe, but there is an increased interest from pharma in being part of this movement. 

• What are the business models and routes to market?
• What are the pros and cons of engaging in telehealth as a pharmaceutical company?
• Who has done this well so far? 
• Do telehealth companies want to partner with pharma vs with providers?